9II Stock Chart & Stats
€0.03
<€0.01(3.03%)
At close: 4:00 PM EDT
€0.03
<€0.01(3.03%)
Day’s Range― - ―
52-Week Range<€0.01 - €0.04
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€10.90M
Enterprise Value€36.05
Total Cash (Recent Filing)€70.41M
Total Debt (Recent Filing)€4.30M
Price to Earnings (P/E)―
Beta8.84
Next Earnings
Sep 10, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.36
Shares Outstanding277,487,200
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.95
Price to Sales (P/S)6.14
P/FCF Ratio-1.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)€2.31M
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthAccelerating revenue growth indicates improving commercial traction for the company’s diagnostics offering. If sustained, expanding sales can increase operating leverage, support broader customer adoption, and provide a foundation for eventual profitability as the business scales.
Low Leverage And Positive EquityThe modest debt burden and positive equity position provide a financial cushion relative to a highly leveraged structure. This reduces immediate balance-sheet pressure and preserves more flexibility to fund commercialization and development while the company works toward profitability.
Focused Oncology Diagnostics PlatformDiviTum targets a clear clinical need by measuring tumor cell proliferation activity from blood samples during oncology treatment. Its positioning across therapy monitoring, clinical research, and potential routine care creates multiple durable avenues for product utilization.
Bears Say
Persistent Large LossesLarge recurring net and operating losses show that revenue growth has not yet translated into a sustainable earnings model. Continued losses can consume equity, limit strategic flexibility, and make the path to breakeven dependent on substantial future operating improvement.
Ongoing Cash BurnConsistently negative operating and free cash flow means the company is not yet funding its activities internally. Continued cash burn increases dependence on future financing or stronger commercial execution, creating a persistent constraint until cash generation improves.
Deeply Negative Margins And ReturnsA negative gross margin indicates that reported cost of sales or related service costs exceeded revenue in 2026, while deeply negative returns show inefficient capital use. Unless unit economics improve, revenue expansion may continue to add scale without producing durable profitability.
Biovica International AB Class B News
9II FAQ
What was Biovica International AB Class B’s price range in the past 12 months?
Biovica International AB Class B lowest stock price was <€0.01 and its highest was €0.04 in the past 12 months.
What is Biovica International AB Class B’s market cap?
Biovica International AB Class B’s market cap is €10.90M.
When is Biovica International AB Class B’s upcoming earnings report date?
Biovica International AB Class B’s upcoming earnings report date is Sep 10, 2026 which is tomorrow.
How were Biovica International AB Class B’s earnings last quarter?
Biovica International AB Class B released its earnings results on Jun 17, 2026. The company reported -€0.006 earnings per share for the quarter.
Is Biovica International AB Class B overvalued?
According to Wall Street analysts Biovica International AB Class B’s price is currently Overvalued.
Does Biovica International AB Class B pay dividends?
Biovica International AB Class B does not currently pay dividends.
What is Biovica International AB Class B’s EPS estimate?
Biovica International AB Class B’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biovica International AB Class B have?
Biovica International AB Class B has 277,487,200 shares outstanding.
What happened to Biovica International AB Class B’s price movement after its last earnings report?
Biovica International AB Class B reported an EPS of -€0.006 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Biovica International AB Class B?
Currently, no hedge funds are holding shares in DE:9II
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Biovica International AB Class B
Biovica International AB (publ) operates as a biotechnology enterprise, concentrating on the development and market introduction of sophisticated blood-based biomarker tests. These diagnostic solutions aim to enhance the tracking and prediction of cancer treatment efficacy across Sweden and globally, with a significant focus on breast cancer. A key offering is DiviTum, a biomarker assay engineered to measure the activity levels of the enzyme thymidine kinase-1 within blood serum or cell cultures. The company's clientele includes oncology research centers, pharmaceutical corporations, and various collaborative organizations. Established in 2008, Biovica's main office is situated in Uppsala, Sweden.
Technical Analysis
Elicera Therapeutics AB
―
Spago Nanomedical AB
―
Cantargia AB
―
Sprint Bioscience AB
―
Fluicell AB
―